Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo

Journal of Immunology

Volumn 185, Issue 2, 2010, Pages 1114-1123

  Santiago, Mario L ^a   Benitez, Robert L ^c   Montano, Mauricio ^c   Hasenkrug, Kim J ^d   Greenex, Warner C ^b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAPTEN; IMMUNOGLOBULIN G1 ANTIBODY; 4 HYDROXY 5 NITROPHENYL ACETIC ACID; 4-HYDROXY-5-NITROPHENYL ACETIC ACID; APOBEC3 PROTEIN, MOUSE; CYTIDINE DEAMINASE; NEUTRALIZING ANTIBODY; NITROPHENOL; PHENYLACETIC ACID DERIVATIVE; VIRUS ANTIBODY;

ANTIBODY AFFINITY; APOBEC3 GENE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BONE MARROW CELL; CELL SUBPOPULATION; ERYTHROID CELL; GENE; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RETROVIRUS INFECTION; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; EXPERIMENTAL LEUKEMIA; FEMALE; FLOW CYTOMETRY; FRIEND LEUKEMIA VIRUS; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; VIRUS INFECTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; BONE MARROW CELLS; CYTIDINE DEAMINASE; FEMALE; FLOW CYTOMETRY; FRIEND MURINE LEUKEMIA VIRUS; HUMANS; IMMUNIZATION; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NITROPHENOLS; PHENYLACETATES; RETROVIRIDAE INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; TUMOR VIRUS INFECTIONS;

EID: 77955490102     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001143     Document Type: Article

References (63)

1. Hasenkrug, K. J., and U. Dittmer. 2007. Immune control and prevention of chronic Friend retrovirus infection. Front. Biosci. 12: 1544-1551.
2. Miyazawa, M., S. Tsuji-Kawahara, and Y. Kanari. 2008. Host genetic factors that control immune responses to retrovirus infections. Vaccine 26: 2981-2996.
3. Lilly, F. 1970. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J. Natl. Cancer Inst. 45: 163-169.
4. Persons, D. A., R. F. Paulson, M. R. Loyd, M. T. Herley, S. M. Bodner, A. Bernstein, P. H. Correll, and P. A. Ney. 1999. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat. Genet. 23: 159-165.
5. Chesebro, B., and K. Wehrly. 1976. Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J. Exp. Med. 143: 85-99.
6. Chesebro, B., and K. Wehrly. 1979. Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc. Natl. Acad. Sci. USA 76: 425-429.
7. Hasenkrug, K. J., A. Valenzuela, V. A. Letts, J. Nishio, B. Chesebro, and W. N. Frankel. 1995. Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J. Virol. 69: 2617-2620.
8. Super, H. J., K. J. Hasenkrug, S. Simmons, D. M. Brooks, R. Konzek, K. D. Sarge, R. I. Morimoto, N. A. Jenkins, D. J. Gilbert, N. G. Copeland, et al. 1999. Fine mapping of the Friend retrovirus resistance gene, Rfv3, on mouse chromosome 15. J. Virol. 73: 7848-7852.
9. Kanari, Y., M. Clerici, H. Abe, H. Kawabata, D. Trabattoni, S. L. Caputo, F. Mazzotta, H. Fujisawa, A. Niwa, C. Ishihara, et al. 2005. Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS 19: 1015-1024.
10. Santiago, M. L., M. Montano, R. Benitez, R. J. Messer, W. Yonemoto, B. Chesebro, K. J. Hasenkrug, and W. C. Greene. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321: 1343-1346.
11. Santiago, M. L., and W. C. Greene. 2008. The role of the Apobec3 family of cytidine deaminases in innate immunity, G-to-A hypermutation and evolution of retroviruses. In Origin and Evolution of Viruses. E. Domingo, C. R. Parrish, and J. J. Holland, eds. Academic Press, London, p. 183-206.
12. Bishop, K. N., M. Verma, E. Y. Kim, S. M. Wolinsky, and M. H. Malim. 2008. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4: e1000231.
13. Soros, V. B., W. Yonemoto, and W. C. Greene. 2007. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3: e15.
14. Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen-Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
15. Lecossier, D., F. Bouchonnet, F. Clavel, and A. J. Hance. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300: 1112.
16. Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103. (Pubitemid 36834849)
17. Zhang, H., B. Yang, R. J. Pomerantz, C. Zhang, S. C. Arunachalam, and L. Gao. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98. (Pubitemid 36834848)
18. Mbisa, J. L., R. Barr, J. A. Thomas, N. Vandegraaff, I. J. Dorweiler, E. S. Svarovskaia, W. L. Brown, L. M. Mansky, R. J. Gorelick, R. S. Harris, et al. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81: 7099-7110.
19. Luo, K., T. Wang, B. Liu, C. Tian, Z. Xiao, J. Kappes, and X. F. Yu. 2007. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81: 7238-7248.
20. Okeoma, C. M., J. Petersen, and S. R. Ross. 2009. Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J. Virol. 83: 3029-3038.
21. Takeda, E., S. Tsuji-Kawahara, M. Sakamoto, M. A. Langlois, M. S. Neuberger, C. Rada, and M. Miyazawa. 2008. Mouse APOBEC3 restricts Friend leukemia virus infection and pathogenesis in vivo. J. Virol. 82: 10998-11008.
22. Abudu, A., A. Takaori-Kondo, T. Izumi, K. Shirakawa, M. Kobayashi, A. Sasada, K. Fukunaga, and T. Uchiyama. 2006. Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr. Biol. 16: 1565-1570.
23. Conticello, S. G., C. J. Thomas, S. K. Petersen-Mahrt, and M. S. Neuberger. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22: 367-377.
24. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563.
25. Low, A., C. M. Okeoma, N. Lovsin, M. de las Heras, T. H. Taylor, B. M. Peterlin, S. R. Ross, and H. Fan. 2009. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385: 455-463.
26. Okeoma, C. M., N. Lovsin, B. M. Peterlin, and S. R. Ross. 2007. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445: 927-930.
27. Jacob, J., G. Kelsoe, K. Rajewsky, and U. Weiss. 1991. Intraclonal generation of antibody mutants in germinal centres. Nature 354: 389-392. (Pubitemid 21896846)
28. Smith, K. G., U. Weiss, K. Rajewsky, G. J. Nossal, and D. M. Tarlinton. 1994. Bcl-2 increases memory B cell recruitment but does not perturb selection in germinal centers. Immunity 1: 803-813.
29. Matsumoto, M., S. F. Lo, C. J. Carruthers, J. Min, S. Mariathasan, G. Huang, D. R. Plas, S. M. Martin, R. S. Geha, M. H. Nahm, and D. D. Chaplin. 1996. Affinity maturation without germinal centres in lymphotoxin-alpha- deficient mice. Nature 382: 462-466.
30. Herzenberg, L. A., S. J. Black, T. Tokuhisa, and L. A. Herzenberg. 1980. Memory B cells at successive stages of differentiation: affinity maturation and the role of IgD receptors. J. Exp. Med. 151: 1071-1087.
31. Furukawa, K., A. Akasako-Furukawa, H. Shirai, H. Nakamura, and T. Azuma. 1999. Junctional amino acids determine the maturation pathway of an antibody. Immunity 11: 329-338. (Pubitemid 29463241)
32. Shimizu, T., M. Oda, and T. Azuma. 2003. Estimation of the relative affinity of B cell receptor by flow cytometry. J. Immunol. Methods 276: 33-44. (Pubitemid 36513835)
33. Doig, D., and B. Chesebro. 1979. Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice: identification of Rfv-3 as a gene locus influencing antibody production. J. Exp. Med. 150: 10-19.
34. Britt, W. J., and B. Chesebro. 1983. Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J. Immunol. 130: 2363-2367.
35. + T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J. Virol. 82: 408-418.
36. Marques, R., I. Antunes, U. Eksmond, J. Stoye, K. Hasenkrug, and G. Kassiotis. 2008. B lymphocyte activation by coinfection prevents immune control of Friend virus infection. J. Immunol. 181: 3432-3440.
37. Chesebro, B., W. Britt, L. Evans, K. Wehrly, J. Nishio, and M. Cloyd. 1983. Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of Friend MCF and Friend ecotropic murine leukemia virus. Virology 127: 134-148. (Pubitemid 13058255)
38. Mikl, M. C., I. N. Watt, M. Lu, W. Reik, S. L. Davies, M. S. Neuberger, and C. Rada. 2005. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell. Biol. 25: 7270-7277.
39. + T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. J. Virol. 76: 450-454.
40. Takahashi, Y., P. R. Dutta, D. M. Cerasoli, and G. Kelsoe. 1998. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J. Exp. Med. 187: 885-895.
41. Naito, Y., H. Takematsu, S. Koyama, S. Miyake, H. Yamamoto, R. Fujinawa, M. Sugai, Y. Okuno, G. Tsujimoto, T. Yamaji, et al. 2007. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol. Cell. Biol. 27: 3008-3022.
42. Hunziker, L., M. Recher, A. J. Macpherson, A. Ciurea, S. Freigang, H. Hengartner, and R. M. Zinkernagel. 2003. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat. Immunol. 4: 343-349.
43. Klinman, D. M., and H. C. Morse III. 1989. Characteristics of B cell proliferation and activation in murine AIDS. J. Immunol. 142: 1144-1149.
44. Morgado, M. G., P. Cam, C. Gris-Liebe, P. A. Cazenave, and E. Jouvin-Marche. 1989. Further evidence that BALB/c and C57BL/6 gamma 2a genes originate from two distinct isotypes. EMBO J. 8: 3245-3251.
45. MacLennan, I. C., K. M. Toellner, A. F. Cunningham, K. Serre, D. M. Sze, E. Zúñiga, M. C. Cook, and C. G. Vinuesa. 2003. Extrafollicular antibody responses. Immunol. Rev. 194: 8-18.
46. Montes, C. L., E. V. Acosta-Rodríguez, M. C. Merino, D. A. Bermejo, and A. Gruppi. 2007. Polyclonal B cell activation in infections: infectious agents' devilry or defense mechanism of the host? J. Leukoc. Biol. 82: 1027-1032.
47. Coutelier, J. P., P. G. Coulie, P. Wauters, H. Heremans, and J. T. van der Logt. 1990. In vivo polyclonal B-lymphocyte activation elicited by murine viruses. J. Virol. 64: 5383-5388.
48. Balkow, S., F. Krux, K. Loser, J. U. Becker, S. Grabbe, and U. Dittmer. 2007. Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. Blood 110: 3949-3958. (Pubitemid 350248450)
49. King, C., S. G. Tangye, and C. R. Mackay. 2008. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu. Rev. Immunol. 26: 741-766.
50. Hasenkrug, K. J., D. M. Brooks, M. N. Robertson, R. V. Srinivas, and B. Chesebro. 1998. Immunoprotective determinants in Friend murine leukemia virus envelope protein. Virology 248: 66-73. (Pubitemid 28393930)
51. Crooks, E. T., P. L. Moore, M. Franti, C. S. Cayanan, P. Zhu, P. Jiang, R. P. de Vries, C. Wiley, I. Zharkikh, N. Schülke, et al. 2007. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366: 245-262.
52. Hammonds, J., X. Chen, X. Zhang, F. Lee, and P. Spearman. 2007. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 25: 8036-8048. (Pubitemid 47632992)
53. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9: 1404-1407.
54. Zheng, Y. H., D. Irwin, T. Kurosu, K. Tokunaga, T. Sata, and B. M. Peterlin. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78: 6073-6076.
55. Stopak, K., C. de Noronha, W. Yonemoto, and W. C. Greene. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12: 591-601.
56. Marin, M., K. M. Rose, S. L. Kozak, and D. Kabat. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9: 1398-1403.
57. Conticello, S. G., R. S. Harris, and M. S. Neuberger. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13: 2009-2013.
58. Mehle, A., B. Strack, P. Ancuta, C. Zhang, M. McPike, and D. Gabuzda. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279: 7792-7798.
59. Lane, H. C., H. Masur, L. C. Edgar, G. Whalen, A. H. Rook, and A. S. Fauci. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309: 453-458.
60. Moir, S., and A. S. Fauci. 2008. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J. Allergy Clin. Immunol. 122:12-19; quiz 20-21.
61. Levesque, M. C., M. A. Moody, K. K. Hwang, D. J. Marshall, J. F. Whitesides, J. D. Amos, T. C. Gurley, S. Allgood, B. B. Haynes, N. A. Vandergrift, et al. 2009. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 6: e1000107.
62. Schmitt, K., M. S. Hill, A. Ruiz, N. Culley, D. M. Pinson, S. W. Wong, and E. B. Stephens. 2009. Mutations in the highly conserved SLQYLA motif of Vif in a simian-human immunodeficiency virus result in a less pathogenic virus and are associated with G-to-A mutations in the viral genome. Virology 383: 362-372.
63. Tsuji-Kawahara, S., T. Chikaishi, E. Takeda, M. Kato, S. Kinoshita, E. Kajiwara, S. Takamura, and M. Miyazawa. 2010. Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in Friend virus-infected mice. J. Virol. 84: 6082-6095.